Smofkabiven 0.061 g (Magnesium Sulfate EMULSION) 0.061 G

SMOFKABIVEN 0.061 G is an intravenous emulsion containing magnesium sulfate, designed for nutritional support. This product is formulated to provide essential nutrients for patients requiring parenteral nutrition.

Strength

0.061 G

Pack Size

986/1477/1970/2463ML

Manufacturer / TM Owner

FRESENIUS KABI CANADA LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

SMOFKABIVEN 0.061 G is used as part of a comprehensive parenteral nutrition regimen. It supplies magnesium, which is crucial for various bodily functions, including muscle and nerve function, blood glucose control, and blood pressure regulation. This emulsion is typically administered to patients who cannot obtain adequate nutrition through oral or enteral means.

Side Effects

When administered intravenously, SMOFKABIVEN 0.061 G provides magnesium sulfate, which supports overall nutritional health. Patients may experience improved muscle function and nerve health as a result of adequate magnesium levels. However, individual responses can vary.

Precautions & Warnings

SMOFKABIVEN 0.061 G should be used under medical supervision. It is essential to monitor magnesium levels to avoid potential imbalances. Patients with kidney issues or those on certain medications should exercise caution. Always follow healthcare provider instructions for safe administration.

Avoid Interactions

Magnesium sulfate can interact with various medications, including diuretics, antibiotics, and heart medications. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare provider.

Frequently Asked Questions

SMOFKABIVEN 0.061 G is used as part of parenteral nutrition to provide magnesium sulfate, supporting muscle and nerve function in patients who cannot obtain adequate nutrition through oral or enteral means.

SMOFKABIVEN 0.061 G is administered intravenously under medical supervision.

Common effects include improved muscle and nerve function due to the provision of magnesium sulfate.

Yes, it should be used under medical supervision, and magnesium levels should be monitored to avoid imbalances.

Yes, it can interact with diuretics, antibiotics, and heart medications, among others.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.